The efficacy of anti-PD-1 agents in acral and mucosal melanoma
Antineoplastic Combined Chemotherapy Protocols
Programmed Cell Death 1 Receptor
Response rates to PD-1 blockade in patients with acral and mucosal melanomas were comparable to the published rates in patients with cutaneous melanoma and support the routine use of PD-1 blockade in clinical practice. Further investigation is needed to identify the mechanisms of response and resistance to therapy in these subtypes. Cancer 2016;122:3354-3362. © 2016 American Cancer Society.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency